Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 8/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199925 | 0.75 | ALDH1A1 (0.40) | ALDH1A1HPGDUSP2LMNAHSD17B10 | |
| SCHEMBL12340471 | 0.75 | CYP1A2 (0.42) | CYP1A2TMIGD3CYP2C9ADORA1ALDH1A1 | |
| SCHEMBL9902092 | 0.75 | CYP1A2 (0.42) | CYP1A2TMIGD3CYP2C9ADORA1ALDH1A1 | |
| SCHEMBL21841298 | 0.73 | BCL2 (0.41) | CYP1A2TMIGD3CYP2C9ADORA1ALDH1A1 | |
| SCHEMBL14434857 | 0.73 | CYP1A2 (0.41) | CYP1A2TMIGD3CYP2C9ADORA1ALDH1A1 | |
| SCHEMBL10110373 | 0.72 | ACVR1 (0.31) | — | |
| SCHEMBL21741322 | 0.69 | GCGR (0.37) | — | |
| SCHEMBL13911355 | 0.68 | HPGD (0.46) | CYP1A2TMIGD3CYP2C9ADORA1ALDH1A1 | |
| SCHEMBL4962059 | 0.67 | TYR (0.30) | HPGDUSP2LMNAHSD17B10 | |
| SCHEMBL20327126 | 0.67 | CDK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263648-B2 | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 | Mylan Laboratories Ltd. (IN) | 2012-09-11 | — | — | US | disclosed |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | PDE4A, PDE4B, PDE12 | CYP1A2 886/4885TMIGD3 3175/4885CYP2C9 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.